Interactive tool · Alpha
Drybench Patent.
Explore patents and exclusivities recorded in the captured FDA files, with each supported date traced to its rule and source row.
Example data: Eliquis (apixaban), from the FDA capture. FDA Orange Book September 2026 files, captured 14 October 2026. Mechanically transcribed; independent regulatory review is pending.
- Free to use
- Runs in your browser
- Transparent methods
Illustration · Explore the real workspace below
See the tools at work.
What you can do with it
A range, never one date
The earliest and latest dates the FDA's rows give, each named by its rule, so the last patent is never mistaken for the day protection ends.
Every date traced
Each date carries the source file, the row, the file's own date when known, the capture date and the checksum, so you can check it against the FDA's file.
Patents as listed
Listed patents with their substance, product and use flags, pediatric rows as the FDA lists them, and delist requests and use codes kept in view.
Exclusivities with codes
Each non-patent exclusivity with the FDA's definition of its code, and NCE-1 computed with its definition shown.
Generics and Paragraph IV
Candidate ANDA rows matched by ingredient and dosage form, with listed therapeutic-equivalence codes; these are not confirmed reference-product links, beside the Paragraph IV list's row for the product.
Biologics from the Purple Book
Reference-product, interchangeable and orphan exclusivity dates where the FDA lists them, with the gaps stated.
A date window
Listed dates from captured rows between two dates, with the rule behind each entry and the applicant as listed.
What changed
Rows added, removed or changed in the FDA's files between captures, for one product or across the whole file.
Start with a worked example
Explore a configured workflow with its starting data and methods ready to inspect.
- Public source data
GLP1 and GIP US Listed Patents and Exclusivity Viewer
Inspect selected GLP1 and GIP product records in an interactive US FDA data workspace. Review listed patents and exclusivities with source dates and coverage.
Starting data: Selected US incretin applications from FDA source files
Explore example
See the evidence behind the answer.
Explore the methods and sources behind the tools.
Read the methodsWhere every panel's data comes from
FDA Orange Book data files (products, patents and exclusivities)
FDA Orange Book data files (products, patents and exclusivities)US government work, public domain (FDA website policies); the classification of this source is held for the General CounselEvery approved drug product with its listed patents, their flags and expiry dates, and its non-patent exclusivities, captured daily and kept on change
Data from the FDA Orange Book data files, U.S. Food and Drug Administration. Not endorsed by the FDA.
FDA Purple Book data download
FDA Purple Book data downloadUS government work, public domain (FDA website policies); the classification of this source is held for the General CounselLicensed biological products with their reference-product, interchangeable and orphan exclusivity dates where FDA lists them, captured on change
Data from the FDA Purple Book, U.S. Food and Drug Administration. Not endorsed by the FDA.
FDA Paragraph IV patent certifications list
FDA Paragraph IV patent certifications listUS government work, public domain (FDA website policies); the classification of this source is held for the General CounselThe first Paragraph IV submission date, the number of ANDAs, the 180-day status and the related dates for each reference listed drug, as FDA publishes them, captured on change
Data from the FDA Paragraph IV patent certifications list, U.S. Food and Drug Administration. Not endorsed by the FDA.
Where it runs and what it sends
This app declares no external public data hosts.
Anything in the address bar before the # (a search, a SMILES, an accession or a step) is sent to this site's host when a page loads or a link is opened; anything after the # is not sent.
Not used, by licence:
- DrugPatentWatch, Pharsight (GreyB), Patsnap and Evaluate. Subscription services and third-party aggregators; never read, seeded, compared or used as an oracle (research 9.5).
- Patent full text, claims and families (USPTO, EPO, Google Patents, Lens). Not US public-domain data as a set and outside the app's scope; a patent number links out as navigation only.
- Court records (PACER) and litigation trackers. Litigation is not in the FDA's files; no estimate covers a curated litigation line, so none is shown.
- Company filings as a data source. A company-disclosed date is a hand-curated quotation of one filing per product, planned for a curated set; none ships until that set exists.
Built for research and education. The tools have not been validated for regulated use. Read the regulatory position
Make your next step a practical one.
Open the app and explore the example.